135 related articles for article (PubMed ID: 36843546)
1. Dedifferentiated Ovarian Carcinoma with ARID1A and ARID1B Mutations: A Clinicopathological Report and Literature Review.
Kamal M; Atwi D; Pang H; Li S; Hassell L
Int J Surg Pathol; 2023 Dec; 31(8):1526-1531. PubMed ID: 36843546
[TBL] [Abstract][Full Text] [Related]
2. Concurrent ARID1A and ARID1B inactivation in endometrial and ovarian dedifferentiated carcinomas.
Coatham M; Li X; Karnezis AN; Hoang LN; Tessier-Cloutier B; Meng B; Soslow RA; Blake Gilks C; Huntsman DG; Stewart CJ; Postovit LM; Köbel M; Lee CH
Mod Pathol; 2016 Dec; 29(12):1586-1593. PubMed ID: 27562491
[TBL] [Abstract][Full Text] [Related]
3. Establishment and characterization of VOA1066 cells: An undifferentiated endometrial carcinoma cell line.
Wang Y; Tao VL; Shin CY; Salamanca C; Chen SY; Chow C; Köbel M; Ben-Neriah S; Farnell D; Steidl C; Mcalpine JN; Gilks CB; Huntsman DG
PLoS One; 2020; 15(10):e0240412. PubMed ID: 33052929
[TBL] [Abstract][Full Text] [Related]
4. Undifferentiated Endometrial Carcinomas Show Frequent Loss of Core Switch/Sucrose Nonfermentable Complex Proteins.
Köbel M; Hoang LN; Tessier-Cloutier B; Meng B; Soslow RA; Stewart CJR; Lee CH
Am J Surg Pathol; 2018 Jan; 42(1):76-83. PubMed ID: 28863077
[TBL] [Abstract][Full Text] [Related]
5. Dedifferentiated and Undifferentiated Ovarian Carcinoma: An Aggressive and Molecularly Distinct Ovarian Tumor Characterized by Frequent SWI/SNF Complex Inactivation.
Tessier-Cloutier B; Kommoss FKF; Kolin DL; Němejcová K; Smith D; Pors J; Stewart CJR; McCluggage WG; Foulkes WD; von Deimling A; Köbel M; Lee CH
Mod Pathol; 2024 Jan; 37(1):100374. PubMed ID: 37925057
[TBL] [Abstract][Full Text] [Related]
6. Loss of ARID1B and SMARCB1 expression are specific for the diagnosis of dedifferentiated/undifferentiated carcinoma in tumours of the upper gynaecological tract and cervix.
Kang EY; Tessier-Cloutier B; Duggan MA; Stewart CJR; Lee CH; Köbel M
Histopathology; 2021 Aug; 79(2):160-167. PubMed ID: 33432679
[TBL] [Abstract][Full Text] [Related]
7. Dedifferentiated endometrial carcinomas with neuroendocrine features: a clinicopathologic, immunohistochemical, and molecular genetic study.
Espinosa I; De Leo A; D'Angelo E; Rosa-Rosa JM; Corominas M; Gonzalez A; Palacios J; Prat J
Hum Pathol; 2018 Feb; 72():100-106. PubMed ID: 29133142
[TBL] [Abstract][Full Text] [Related]
8. Clinicopathological significance of multiple molecular features in undifferentiated and dedifferentiated endometrial carcinomas.
Zhang K; Liu Y; Liu X; Du J; Wang Y; Yang J; Li Y; Liu C
Pathology; 2021 Feb; 53(2):179-186. PubMed ID: 33070954
[TBL] [Abstract][Full Text] [Related]
9. Mutation and loss of expression of ARID1A in uterine low-grade endometrioid carcinoma.
Guan B; Mao TL; Panuganti PK; Kuhn E; Kurman RJ; Maeda D; Chen E; Jeng YM; Wang TL; Shih IeM
Am J Surg Pathol; 2011 May; 35(5):625-32. PubMed ID: 21412130
[TBL] [Abstract][Full Text] [Related]
10. BRG1, INI1, and ARID1B Deficiency in Endometrial Carcinoma: A Clinicopathologic and Immunohistochemical Analysis of a Large Series From a Single Institution.
Kihara A; Amano Y; Matsubara D; Fukushima N; Fujiwara H; Niki T
Am J Surg Pathol; 2020 Dec; 44(12):1712-1724. PubMed ID: 32910019
[TBL] [Abstract][Full Text] [Related]
11. Dedifferentiated endometrioid adenocarcinoma of the uterus: a clinicopathologic study of a case.
Vita G; Borgia L; Di Giovannantonio L; Bisceglia M
Int J Surg Pathol; 2011 Oct; 19(5):649-52. PubMed ID: 21531695
[TBL] [Abstract][Full Text] [Related]
12. Pattern of SMARCB1 (INI1) and SMARCA4 (BRG1) in poorly differentiated endometrioid adenocarcinoma of the uterus: analysis of a series with emphasis on a novel SMARCA4-deficient dedifferentiated rhabdoid variant.
Strehl JD; Wachter DL; Fiedler J; Heimerl E; Beckmann MW; Hartmann A; Agaimy A
Ann Diagn Pathol; 2015 Aug; 19(4):198-202. PubMed ID: 25920939
[TBL] [Abstract][Full Text] [Related]
13. Ovarian and endometrial endometrioid adenocarcinomas have distinct profiles of microsatellite instability, PTEN expression, and ARID1A expression.
Huang HN; Lin MC; Tseng LH; Chiang YC; Lin LI; Lin YF; Huang HY; Kuo KT
Histopathology; 2015 Mar; 66(4):517-28. PubMed ID: 25195947
[TBL] [Abstract][Full Text] [Related]
14. ARID1A mutations in endometriosis-associated ovarian carcinomas.
Wiegand KC; Shah SP; Al-Agha OM; Zhao Y; Tse K; Zeng T; Senz J; McConechy MK; Anglesio MS; Kalloger SE; Yang W; Heravi-Moussavi A; Giuliany R; Chow C; Fee J; Zayed A; Prentice L; Melnyk N; Turashvili G; Delaney AD; Madore J; Yip S; McPherson AW; Ha G; Bell L; Fereday S; Tam A; Galletta L; Tonin PN; Provencher D; Miller D; Jones SJ; Moore RA; Morin GB; Oloumi A; Boyd N; Aparicio SA; Shih IeM; Mes-Masson AM; Bowtell DD; Hirst M; Gilks B; Marra MA; Huntsman DG
N Engl J Med; 2010 Oct; 363(16):1532-43. PubMed ID: 20942669
[TBL] [Abstract][Full Text] [Related]
15. Dedifferentiated carcinoma with clear cell carcinoma of the endometrium: A case report.
Lee SE; Park HY; Shim SH; Kim WY
Pathol Int; 2017 Sep; 67(9):472-476. PubMed ID: 28667682
[TBL] [Abstract][Full Text] [Related]
16. Ovarian and endometrial endometrioid carcinomas have distinct CTNNB1 and PTEN mutation profiles.
McConechy MK; Ding J; Senz J; Yang W; Melnyk N; Tone AA; Prentice LM; Wiegand KC; McAlpine JN; Shah SP; Lee CH; Goodfellow PJ; Gilks CB; Huntsman DG
Mod Pathol; 2014 Jan; 27(1):128-34. PubMed ID: 23765252
[TBL] [Abstract][Full Text] [Related]
17. ARID1B as a Potential Therapeutic Target for ARID1A-Mutant Ovarian Clear Cell Carcinoma.
Sato E; Nakayama K; Razia S; Nakamura K; Ishikawa M; Minamoto T; Ishibashi T; Yamashita H; Iida K; Kyo S
Int J Mol Sci; 2018 Jun; 19(6):. PubMed ID: 29890703
[TBL] [Abstract][Full Text] [Related]
18. Optimised ARID1A immunohistochemistry is an accurate predictor of ARID1A mutational status in gynaecological cancers.
Khalique S; Naidoo K; Attygalle AD; Kriplani D; Daley F; Lowe A; Campbell J; Jones T; Hubank M; Fenwick K; Matthews N; Rust AG; Lord CJ; Banerjee S; Natrajan R
J Pathol Clin Res; 2018 Jul; 4(3):154-166. PubMed ID: 29659191
[TBL] [Abstract][Full Text] [Related]
19. Endocervical-type mucinous borderline tumors are related to endometrioid tumors based on mutation and loss of expression of ARID1A.
Wu CH; Mao TL; Vang R; Ayhan A; Wang TL; Kurman RJ; Shih IeM
Int J Gynecol Pathol; 2012 Jul; 31(4):297-303. PubMed ID: 22653341
[TBL] [Abstract][Full Text] [Related]
20. Loss of switch/sucrose non-fermenting complex protein expression is associated with dedifferentiation in endometrial carcinomas.
Karnezis AN; Hoang LN; Coatham M; Ravn S; Almadani N; Tessier-Cloutier B; Irving J; Meng B; Li X; Chow C; McAlpine J; Kuo KT; Mao TL; Djordjevic B; Soslow RA; Huntsman DG; Blake Gilks C; Köbel M; Lee CH
Mod Pathol; 2016 Mar; 29(3):302-14. PubMed ID: 26743474
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]